Cardiol Therapeutics Inc. (TSE:CRDL) Senior Officer Bernard Lim Acquires 10,000 Shares of Stock

Cardiol Therapeutics Inc. (TSE:CRDL - Get Free Report) Senior Officer Bernard Lim acquired 10,000 shares of the stock in a transaction dated Tuesday, December 17th. The stock was acquired at an average price of C$1.95 per share, for a total transaction of C$19,500.00.

Cardiol Therapeutics Price Performance

Shares of Cardiol Therapeutics stock traded up C$0.04 during trading hours on Tuesday, hitting C$1.95. The company's stock had a trading volume of 137,013 shares, compared to its average volume of 135,025. The company has a market cap of C$136.27 million, a PE ratio of -4.43 and a beta of 0.70. The company has a debt-to-equity ratio of 1.07, a quick ratio of 6.84 and a current ratio of 2.39. The business has a 50 day moving average price of C$2.41 and a two-hundred day moving average price of C$2.73. Cardiol Therapeutics Inc. has a 12-month low of C$1.07 and a 12-month high of C$4.26.

Cardiol Therapeutics Company Profile

Cardiol Therapeutics Inc, a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.